Autolus Therapeutics Secures 10-Year Critical Lentiviral Vector Supply Agreement with AGC Biologics

summarizeSummary

Autolus Therapeutics plc has entered into a 10-year Master Supply Agreement with AGC Biologics for the critical lentiviral vector, essential for its CAR-T product manufacturing, including AUCATZYL.

check_boxKey Events

• Long-Term Supply Secured

  Autolus Limited, a wholly-owned subsidiary, signed a 10-year Master Supply Agreement with AGC Biologics for the manufacture and supply of lentiviral vector.

• Critical Raw Material

  The lentiviral vector is a critical raw material for manufacturing Autolus's CAR-T products, including the commercial AUCATZYL and clinical trial products.

• Significant Financial Commitment

  The agreement includes a minimum purchase commitment of 14 batches in the first two years and at least EUR 25 million in products and services over the subsequent five-year period.

• Strategic Partnership

  AGC Biologics also gains the first right to negotiate new manufacturing activities for Autolus's obe-cel product.

auto_awesomeAnalysis

Autolus Therapeutics plc has entered into a 10-year Master Supply Agreement with AGC Biologics for the critical lentiviral vector, essential for its CAR-T product manufacturing, including AUCATZYL. This agreement significantly de-risks Autolus's manufacturing supply chain by securing a long-term source for a critical raw material. The commitment of at least EUR 25 million over five years (following an initial two-year period) highlights the strategic importance of this partnership. This ensures stability for the production of its commercial CAR-T product, AUCATZYL, and its clinical pipeline, which is a positive operational development for the company.